Trials / Unknown
UnknownNCT02805738
Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet
A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet and Viread® Tablet in Chronic Hepatitis B Patients
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 158 (estimated)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 tablet
Detailed description
A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 tablet and Viread® tablet in Chronic hepatitis B Patients Subjects will receive either a single oral dose of the test formulation(CKD-390) or a oral dose of the reference formulation(viread).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKD-390 | CKD-390 1 Tablet (48 weeks) |
| DRUG | viread | viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks) |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2017-11-01
- Completion
- 2018-03-01
- First posted
- 2016-06-20
- Last updated
- 2016-06-21
Locations
20 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02805738. Inclusion in this directory is not an endorsement.